Fuat Bicer, Assistant Professor at the Ohio State University Wexner Medical Center, shared a post on X:
“ASCO 2026
Cadonilimab + axitinib in nccRCC:
- ORR ~51%
- G3+ AEs ~60%, worse then Ipi/Nivo
- Promising-but small single race, non-randomized.
- Not practice-changing.
Other articles about ASCO on OncoDaily.